

Press release 2025-06-17

AcuCort signs Letter of Intent (LOI) with Glenmark Pharmaceuticals for Germany and five additional European countries

The pharmaceutical company AcuCort has signed a Letter of Intent (LOI) with the global pharmaceutical company Glenmark Pharmaceuticals. The LOI covers the distribution and marketing of AcuCort's product Zeqmelit® in six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine.

Glenmark Pharmaceuticals is a well-established player in the pharmaceutical industry with a strong presence in several key markets. With operations in over 80 countries, the company represents a strategically important partner for AcuCort.

According to the LOI, Glenmark Pharmaceuticals will be responsible for the commercialisation of Zeqmelit® in the following six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine.

"This agreement covers a total population of more than 160 million people. Launching Zeqmelit® in Germany not only represents significant commercial potential, but also strengthens our position in ongoing discussions with other prospective partners," says Jonas Jönmark, CEO of AcuCort, and continues:

"Our strategy of using the successful launch in the Nordic region as a springboard for further expansion is now bearing fruit. I look forward to announcing additional important partnerships in the future."

The parties intend to finalise negotiations and enter into a definitive commercial agreement during 2025. The signed Letter of Intent confirms the mutual agreement on the key terms and conditions for a future binding commercial agreement.

Zeqmelit® was launched in Sweden, Norway, and Finland in autumn 2024. During spring 2025, additional orders have been placed for the Nordic market, including a new order for Denmark.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is a research-led, global pharmaceutical company operating across branded, generics and OTC segments. The company has focus on therapeutic areas such as respiratory, dermatology and oncology. Glenmark operates four R&D centres and ten world class manufacturing facilities across five continents, with a presence in over 80 countries.

For further information:

Jonas Jönmark, vd, AcuCort AB

Phone: 070 365 5400

E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)



AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.